Wegovy vs Zepbound: Semaglutide and Tirzepatide Compared
A plain-English comparison of Wegovy (semaglutide) and Zepbound (tirzepatide): how they work, weight loss in clinical trials including the head-to-head study, side effects, dosing and other approved uses.
Key points
- Wegovy contains semaglutide. Zepbound contains tirzepatide. Both are weekly injections for weight management.
- In the head-to-head trial, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks.
- Side effects are similar in type: mostly nausea, diarrhea, vomiting and constipation.
- Wegovy also comes as a daily pill and has heart-related approvals. Zepbound is also approved for sleep apnea.
Wegovy and Zepbound are the two best-known prescription medications for weight management in the United States. They belong to the same family and are used in a similar way, but they are different molecules with different trial results. Here is how they compare, based on the US prescribing information and the published trials.
Side by side
| Wegovy | Zepbound | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Maker | Novo Nordisk | Eli Lilly |
| How it works | Activates the GLP-1 receptor | Activates the GIP and GLP-1 receptors |
| How it's taken | Weekly injection, or a daily tablet | Weekly injection |
| Starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Maintenance doses | 1.7 or 2.4 mg weekly; up to 7.2 mg for some adults | 5, 10 or 15 mg weekly |
| Same ingredient for diabetes | Ozempic | Mounjaro |
| Half-life | About 1 week | About 5–6 days |
How they work
Semaglutide copies a gut hormone called GLP-1. It slows stomach emptying and acts on the parts of the brain that control hunger and fullness, so people feel satisfied with less food.
Tirzepatide acts on the GLP-1 receptor too, and also on the receptor for a second hormone, GIP. This is why it is sometimes called a dual agonist. Researchers think the combination explains the larger average weight loss seen in trials.
Weight loss in clinical trials
Each medication was first tested against placebo, alongside a reduced-calorie diet and more physical activity:
- Wegovy 2.4 mg (STEP 1, 68 weeks): average weight change of −14.9%, compared with −2.4% for placebo.
- Zepbound (SURMOUNT-1, 72 weeks): −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, compared with −3.1% for placebo.
Those were separate studies, so they can't be compared exactly. The SURMOUNT-5 trial, published in 2025, tested the two directly in adults with obesity and without diabetes. After 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide, each at the highest dose people could tolerate.
Wegovy's label has since added a higher 7.2 mg weekly dose (sold as Wegovy HD) for adults who have tolerated 2.4 mg for at least four weeks and need further weight reduction. That dose was not part of SURMOUNT-5.
Keep in mind that these are averages. In every trial some people lost much more and some much less, and results depend on staying on treatment.
Side effects
The two share the same main side effects, which mostly affect the stomach and gut and are most likely while the dose is rising.
| Side effect | Wegovy 2.4 mg | Zepbound 5–15 mg |
|---|---|---|
| Nausea | 44% | 25–29% |
| Diarrhea | 30% | 19–23% |
| Vomiting | 24% | 8–13% |
| Constipation | 24% | 11–17% |
Both carry the same boxed warning about thyroid C-cell tumors seen in rodents, and neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Our guide to GLP-1 side effects covers what helps and when to call your doctor.
Slimsy works with both medications, and with a switch between them. Your doses, symptoms and weight stay in one timeline.
Try SlimsyDosing and daily life
Both injections are taken once a week, on the same day, with or without food. Both start low and step up at least four weeks apart. Wegovy has four steps before the 2.4 mg maintenance dose; Zepbound rises in 2.5 mg steps and can stay at 5, 10 or 15 mg. The full schedules are in our GLP-1 dosing chart.
A few practical differences:
- Missed dose: with Wegovy, take it if your next dose is more than 2 days away. With Zepbound, take it within 4 days of the missed dose.
- Out of the fridge: Wegovy pens can be kept at up to 86°F (30°C) for up to 28 days; Zepbound single-dose pens for up to 21 days.
- Pill option: Wegovy is also available as a daily tablet, taken on an empty stomach with a small amount of water, 30 minutes before food. Zepbound has no tablet form.
Other approved uses
Beyond weight management, Wegovy is approved to reduce the risk of major cardiovascular events in adults with heart disease and overweight or obesity, and for a liver condition called MASH. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. These can matter for the choice, and for insurance coverage.
Which one is right for you?
That is a decision to make with your prescriber. The things that usually decide it are your health history, what your insurance covers, what you can get at your pharmacy, how you tolerated earlier medications, and whether a pill matters to you. On average tirzepatide leads to more weight loss, but the best medication is the one you can take consistently and tolerate well.
Whichever you take, the habits that support it are the same: regular doses, enough protein, strength training and an honest record of how you feel.
Frequently asked questions
Is Zepbound more effective than Wegovy?
In the one trial that compared them directly (SURMOUNT-5), people on tirzepatide lost an average of 20.2% of their body weight over 72 weeks and people on semaglutide lost 13.7%. Averages hide a wide range, and some people respond better to semaglutide.
Are Wegovy and Ozempic the same thing?
They contain the same active ingredient, semaglutide. Wegovy is approved for weight management and goes up to higher doses. Ozempic is approved for type 2 diabetes and goes up to 2 mg a week.
Are Zepbound and Mounjaro the same thing?
Both contain tirzepatide at the same doses. Zepbound is approved for weight management and for obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes.
Can I switch between Wegovy and Zepbound?
People do switch in both directions, usually because of side effects, a plateau, cost or insurance coverage. There is no single standard conversion, so the starting dose and timing are decisions for your prescriber.
Sources
- Wegovy (semaglutide) prescribing information, DailyMed, revised June 2026
- Zepbound (tirzepatide) prescribing information, DailyMed, revised August 2026
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022
This article is general information, not medical advice. It was written by the Slimsy team from the sources listed above and has not been reviewed by a medical professional. Prescribing information changes; always follow the Medication Guide that comes with your prescription and your prescriber's instructions.